High-flow Nasal Cannula Market to Witness Exponential Growth by 2025

Posted by Aman Jaiswar on August 13th, 2019

Some of the prominent participants in the global High-flow Nasal Cannula Market are Fisher & Paykel Healthcare Limited, ResMed, Inc., Teijin Pharma Limited, Becton, Dickinson and Company, MEK-ICS CO., LTD., Teleflex Incorporated, Smiths Medical, Vapotherm, Inc., Flexicare Medical Limited, Salter Labs, Hamilton Medical, TNI medical AG, and Great Group Medical Co., Ltd. Of them, Fisher & Paykel Healthcare Limited emerged as the market leader in 2016.

Numerous factors are driving growth in the global high flow nasal cannula market. At the forefront is the ever-increasing number of respiratory disorders. Besides, soaring popularity and uptake of heated humidified high-flow nasal cannulas and increasing investments in research and development programs by companies to come up with better products leveraging more sophisticated technologies is also positively impacting sales. A noticeable trend in the market is the focus of local players on cost-effective products.

A study by Transparency Market Research, predicts the global nasal cannula market to rise at a 11.8% CAGR from 2017 to 2025 to become worth US.08 bn by 2025 from US.42 bn 2016.

Request to View Sample of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28580

The global high-flow nasal cannula market can be segmented based on different parameters. Depending upon component, for example, the market can be divided into air/oxygen blender, nasal cannulas, active humidifier, single heated tube, and other consumables. Of them, the segment of active humidifier held maximum share in the market in 2016 and it was trailed by the segment of air/oxygen blender. In the near future too, active humidifiers will continue to retain their dominant market share on the back of continued innovations in humidifiers by manufacturers and health care solution providers in order to up their efficacy.

Application-wise, the key segments of the global high-flow nasal cannula market are acute respiratory failure, acute heart failure, chronic obstructive pulmonary disease (COPD), carbon monoxide toxicity, sleep apnea, bronchiectasis, etc. The acute respiratory failure segment, of them, held a major share in the market in 2016. It was followed by chronic obstructive pulmonary disease segment. This is because of the rampant acute respiratory failure in newborns, children, and adults. Ambulatory care centers, long-term care centers, hospitals, etc. are some of the main end-users in the global high-flow nasal cannula market.